UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
_________________________________________________________
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
___________________________________________________________________
Date
of
Report (Date of earliest event reported): April
4, 2008
|
Transdel
Pharmaceuticals, Inc.
|
|
|
(Exact
name of registrant as specified in its
charter)
|
|
Delaware
|
000-52998
|
45-0567010
|
|
(State
or other jurisdiction
of
incorporation)
|
(Commission
File
Number)
|
(IRS
Employer
Identification
No.)
|
|
4225
Executive Square, Suite 460
La
Jolla, CA
|
92037
|
|
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
|
Registrant’s
telephone number, including area code: (858)
457-5300
|
|
N/A
|
|
(Former
name or former address, if changed since last
report)
|
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o
Written
communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting
material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement
communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement
communications pursuant
to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
| Item 5.02 |
Departure
of Directors or Certain Officers; Election of Directors; Appointment
of
Certain
Officers; Compensatory Arrangements of Certain
Officers.
|
On
April
4, 2008, Balbir Brar resigned from his position as the vice president of
research and development of Transdel Pharmaceuticals, Inc. (the “Company”), as
well as from any other positions he held at the Company and any of its
subsidiaries or affiliates.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
|
Transdel
Pharmaceuticals, Inc.
|
||
| |
|
|
| Date: April 10, 2008 | By: | /s/ John T. Lomoro |
|
John
T. Lomoro
Chief
Financial Officer
|
||